Comparisons of the side effects of the post-operative chemotherapies in esophageal squamous cell carcinoma patients

LI Shan-shan; LIN Zheng; MA Ming-yang; SU Kun-hui; CHEN Ya-ting; LIU Yong-lan; HU Zhi-jian

doi:10.16462/j.cnki.zhjbkz.2020.07.012

Volume 24 Issue 7

Jul. 2020

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2020 > 24(7): 808-813

LI Shan-shan, LIN Zheng, MA Ming-yang, SU Kun-hui, CHEN Ya-ting, LIU Yong-lan, HU Zhi-jian. Comparisons of the side effects of the post-operative chemotherapies in esophageal squamous cell carcinoma patients[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(7): 808-813. doi: 10.16462/j.cnki.zhjbkz.2020.07.012

Citation:

LI Shan-shan, LIN Zheng, MA Ming-yang, SU Kun-hui, CHEN Ya-ting, LIU Yong-lan, HU Zhi-jian. Comparisons of the side effects of the post-operative chemotherapies in esophageal squamous cell carcinoma patients[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(7): 808-813. doi: 10.16462/j.cnki.zhjbkz.2020.07.012

Citation:

LI Shan-shan, LIN Zheng, MA Ming-yang, SU Kun-hui, CHEN Ya-ting, LIU Yong-lan, HU Zhi-jian. Comparisons of the side effects of the post-operative chemotherapies in esophageal squamous cell carcinoma patients[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(7): 808-813. doi: 10.16462/j.cnki.zhjbkz.2020.07.012

PDF( 1466 KB)

Comparisons of the side effects of the post-operative chemotherapies in esophageal squamous cell carcinoma patients

doi: 10.16462/j.cnki.zhjbkz.2020.07.012

Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou 350122, China

Funds:

Innovative Research Program for Undergraduate of Public Health School of Fujian Medical University 201902

National Key R & D Program of China 2017YFC0907100

2018 Medical Innovation Project of Fujian Province 2018-CX-38

Startup Fund for scientific research, Fujian Medical University 2018QH2012

More Information

Corresponding author: HU Zhi-jian, E-mail:hzj99955888@126.com
Received Date: 2019-11-25
Rev Recd Date: 2020-02-11
Publish Date: 2020-07-10

Abstract

Abstract

Objective To investigate the relationship between post-operative chemotherapy, prognosis and side-effects of esophageal squamous cell carcinoma (ESCC). Methods This study enrolled a total of 188 patients with ESCC in the First Affiliated Hospital of Fujian Medical University and Fujian Cancer Hospital from June 2014 to November 18th 2018. The cumulative survival rates were estimated using the Kaplan-Meier method and comparisons were performed using the log-rank test. The Cox proportional hazards model was performed for analysis of the impact factors of survival and the Kruskal-Wallis H test was used to compare side-effects of chemotherapy regimens. The unconditional Logistic regression was performed to analyze the correlation between postoperative chemotherapy regimens and side-effects. Results The chemotherapy regimen was an independent risk factor for poor survival of ESCC patients. Compared with "docetaxel (DOC)+cisplatin (DDP)/nedaplatin (NDP)" group, ESCC patients in "paclitaxel (PTX)+luoplatinum (LBP)/oxaliplatin (OXA)" group and "DOC +LBP/OXA" group had better overall survival. The post-operative chemotherapy regimen was related to blood/bone marrow abnormalities and other side-effects (χ²=11.741, P=0.008). Compared with "DOC+DDP/NDP" group, "DOC+LBP/OXA" group increased the risk of leukocyte reduction (OR=4.089, 95% CI:1.073~15.585, P=0.039) and decreased the risk of lymphocyte reduction (OR=0.257, 95% CI:0.075~0.878, P=0.030). Conclusions The chemotherapy regimen is the impact factor for the prognosis and side-effects of patients with ESCC. The prognosis of "DOC+LBP/OXA" group and "PTX+LBP/OXA" group is better than "DOC+DDP/NDP" group. The "DOC+LBP/OXA" group reduces the risk of side-effects.
- Esophageal squamous cell carcinoma,
- Chemotherapy regimen,
- Survival analysis,
- Side Effects

FullText(HTML)

References(17)

References

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492.
[2]	Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China in 2013:an analysis based on urbanization level[J]. Chin J Cancer Res, 2017, 29(1):1-10. DOI: 10.21147/j.issn.1000-9604.2017.01.01.
[3]	Kanemura T, Makino T, Miyazaki Y, et al. Distribution patterns of metastases in recurrent laryngeal nerve lymph nodes in patients with squamous cell esophageal cancer[J]. Dis Esophagus, 2017, 30(1):1-7. DOI: 10.1111/dote.12527.
[4]	相智声, 林征, 刘双, 等.术前血清CA19-9和NSE对食管鳞癌患者预后的影响[J].中华疾病控制杂志, 2019, 23(2):134-139. DOI: 10.16462/j.cnki.zhjbkz.2019.02.003. Xiang ZS, Lin Z, Liu S, et al. Prognostic values of preoperative serum CA199 and NSE on esophageal squamous cell carcinoma patients[J]. Chin J Dis Control Prev, 2019, 23(2):134-139. DOI: 10.16462/j.cnki.zhjbkz.2019.02.003.
[5]	Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer[J]. Lancet, 2017, 390(10110):2383-2396. DOI:10.1016-S0140-6736(17)31462-31469.
[6]	Chan KKW, Saluja R, Delos Santos K, et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer:a network meta-analysis[J]. Int J Cancer, 2018, 143(2):430-437. DOI: 10.1002/ijc.31312.
[7]	Chen Y, Zhang Z, Jiang G, et al. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patientstreated with definitive radiotherapy[J]. Thorac Dis, 2016, 8(6):1155-1161. DOI: 10.21037/jtd.2016.04.08.
[8]	National Health Commission of the People's Republic of China. Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018(English version)[J]. Chin J Cancer Res, 2019, 31(2):223-258. DOI: 10.21147/j.issn.1000-9604.2019.02.01.
[9]	U.S. Department of Health and Human Services. Cancer therapy evaluation program, common terminology criteria for adverse events, version 4.0[EB/OL]. (2009-05-28)[2020-02-01]. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
[10]	Courrech Staal EF, Aleman BM, van Velthuysen ML, et al. Chemoradiation for esophageal cancer institutional experience with three different regimens[J]. Am J Clin Oncol, 2011, 34(4):343-349. DOI: 10.1097/COC.0b013e3181dbbafe.
[11]	刘爱娜, 黄镜, 蔡锐刚, 等. 138例晚期食管癌的化疗疗效和预后因素分析[J].癌症, 2008, 27(4):400-406. DOI: 10.3321/j.issn:1000-467X.2008.04.012. Liu AN, Huang J, Cai RG, et al. Responses of advanced esophageal cancer to chemotherapy and prognostic factors:a report of 138 cases[J]. Chin J Cancer, 2008, 27(4):400-406. DOI: 10.3321/j.issn:1000-467X.2008.04.012.
[12]	Xi M, Zhang P, Zhang L, et al. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy[J]. Jpn J Clin Oncol, 2017, 47(8):683-689. DOI: 10.1093/jjco/hyx060.
[13]	刘鲁平, 张玉星.紫杉醇联合洛铂或顺铂治疗晚期非小细胞肺癌48例比较[J].现代肿瘤医学, 2011, 19(1):78-79. DOI: 10.11569/wcjd.v23.i24.3904. Liu LP, Zhang YX. Comparison of paclitaxel combined with luoplatinum or cisplatin in the treatment of 48 patients with advanced non-small-cell lung carcinoma[J]. J Mod Oncol, 2011, 19(1):78-79. DOI: 10.11569/wcjd.v23.i24.3904.
[14]	任超, 周福有.洛铂联合紫杉醇在局部进展期食管癌新辅助治疗中的疗效和安全性观察[J].现代诊断与治疗, 2019, 30(2):248-250. DOI: CNKI:SUN:XDZD.0.2019-02-087. Ren C, Zhou FY. Efficacy and safety observation of luoplatinum combined with Paclitaxel in neoadjuvant treatment of locally advanced esophageal carcinoma[J]. Mod Diagn Treat, 2019, 30(2):248-250. DOI: CNKI:SUN:XDZD.0.2019-02-087.
[15]	Chen J, Su T, Lin Y, et al. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma[J]. Clin Transl Oncol. 2018, 20(3):411-419. DOI: 10.1007/s12094-017-1734-y.
[16]	樊丽萍, 周燕, 赵西侠, 等.奈达铂与洛铂同步放化疗治疗局部晚期宫颈癌的疗效观察[J].中国肿瘤临床与康复, 2017, 24(8):943-946. DOI: 10.13455/j.cnki.cjcor.2017.08.13. Fan LP, Zhou Y, Zhao XY, et al. Efficacy of concurrent chemoradiotherapy with nedaplatin and luoplatinum for locally advanced cervical carcinoma[J]. Chin J Clin Oncol Rehabil, 2017, 24(8):943-946. DOI: 10.13455/j.cnki.cjcor.2017.08.13.
[17]	郭亮, 苏克莉, 牛建花, 等.多西他赛单药化疗与联合铂类一线治疗老年晚期非小细胞肺癌的有效性与安全性研究[J].中国社区医师, 2015, 31(12):38-39. DOI: 10.3969/j.issn.1007-614x.2015.12.22. Guo L, Su KL, Niu JH, et al. Effective and safety study of docetaxel single agent chemotherapy and combined with platinum based first-line in the treatment of elderly patients with advanced non-small cell lung cancer[J]. Chin Comm Doc, 2015, 31(12):38-39. DOI: 10.3969/j.issn.1007-614x.2015.12.22.